Nachrichten zur Gilead Sciences Inc. Aktie

Gilead Sciences, Inc. (GILD) Barclays 26th Annual Global Healthcare Conference (Transcript)

…

Gilead Sciences, Inc. (GILD) Leerink Partners Global Biopharma Conference (Transcript)

…

Oppenheimer remain bullish on Gilead Sciences , HIV agents in 24/25 could provide conviction to investors By Investing.com

Oppenheimer remain bullish on Gilead Sciences , HIV agents in 24/25 could provide conviction to investors…

Aktienmarkt: Aktie von Gilead Sciences tritt auf der Stelle (66,7052 €)

Wenig Kursbewegung derzeit bei der Gilead Sciences-Aktie . Das Papier notiert aktuell bei 72,68 US-Dollar. Kaum auffällig ist zur Stunde…

Gilead Sciences, Inc. (GILD) Presents at TD Cowen 44th Annual Health Care Conference (Transcript)

…

CymaBay Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Corporate Update

Gilead Sciences, Inc. has proposed to acquire CymaBay for $32.50 per share in cash or a total equity value of…

Biocytogen und Gilead schließen ein Abkommen über die Zusammenarbeit bei Multi-Target-Antikörpern

BEIJING--(BUSINESS WIRE)--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) gibt heute den Abschluss einer Vereinbarung mit Gilead Sciences, Inc. über…

Gilead Sciences: 2024 Catalysts Should Drive Growth And Change In Sentiment

…

Gilead Sciences: Sinnvolle Übernahme - Aktienanalyse

San Francisco (www.aktiencheck.de) - Gilead Sciences-Aktienanalyse von Wells Fargo Advisors: Mohit Bansal, Analyst von Wells Fargo Advisors, nimmt in einer aktuellen…

Gilead Sciences to acquire CymaBay Therapeutics in $4.3bn cash deal By Investing.com

Gilead Sciences to acquire CymaBay Therapeutics in $4.3bn cash deal…

Gilead Sciences: Cheap For A Reason

…

The Zacks Analyst Blog Highlights Gilead Sciences, Bristol Myers, Amgen, Morphysys and REGENXBIO

Gilead Sciences, Bristol Myers, Amgen, Morphysys and REGENXBIO are included in this Analyst Blog.…

Gilead Sciences, Inc. (GILD) Q4 2023 Earnings Call Transcript

…

Gilead Sciences, Inc. 2023 Q4 - Results - Earnings Call Presentation

…

Gilead Sciences Q4 earnings fall short of estimates By Investing.com

Gilead Sciences Q4 earnings fall short of estimates…

Gilead Sciences raises dividend by 2.7% to $0.77 a share By Investing.com

Gilead Sciences raises dividend by 2.7% to $0.77 a share…

Gilead Sciences: 85 oder 75 USD? Kursziele und Ratings der Analysten vor Q4-Zahlen auf einen Blick - Aktiennews

Foster City (www.aktiencheck.de) - Welche Kursziele und Ratings trauen die Analysten der führenden Banken und Research-Häuser der Aktie des biopharmazeutischen…

Gilead Sciences stock trading in the red for seventh straight session

…

Arcus Biosciences: Did Gilead Sciences overpay for its latest investment?

…

Arcus rises, Gilead slips on expanded agreement

Shares in Arcus Biosciences Inc rose after Gilead Sciences Inc (NASDAQ:GILD, ETR:GIS) agreed to invest another $320 million as part of a…

Gilead Sciences raises stake in cancer-centric Arcus Biosciences to 33%

Gilead Sciences said on Monday it has raised its stake in Arcus Biosciences to 33% and expanded its presence in…

Gilead Sciences: Neues Kursziel

London (www.aktiencheck.de) - Rating-Update: Barclays stuft die Aktie von Gilead Sciences Inc. (ISIN: US3755581036, WKN 885823, Ticker-Symbol: GIS, NASDAQ-Symbol: GILD) nach…

Biotech Stock Roundup: GILD Down on Study Results, INBX Gains on Sanofi Deal & More

Gilead Sciences (GILD) and Inhibrx (INBX) are in the spotlight on regulatory and pipeline updates.…

Gilead Sciences: Überreaktion - Aktienanalyse

New York (www.aktiencheck.de) - Gilead Sciences-Aktienanalyse von Evercore ISI: Evercore ISI nimmt in einer aktuellen Aktienanalyse die Aktie von Gilead Sciences…

Gilead (GILD) Down as NSCLC Study Fails to Meet Primary Goal

Gilead Sciences (GILD) phase III study evaluating Trodelvy (sacituzumab govitecan) in previously treated metastatic NSCLC fails to meet its primary…

Gilead shares plunge on lung cancer trial disappointment

Gilead Sciences Inc (NASDAQ:GILD, ETR:GIS) shares fell by their most since 2015 as the late-stage trial of its antibody-drug conjugate…

Stocks making the biggest moves midday: Vita Coco, Archer-Daniels-Midland, Gilead Sciences and more

These are the stocks posting the largest moves in midday trading.…

Gilead Sciences shares fall sharply after lung cancer drug trial fails By Investing.com

Gilead Sciences shares fall sharply after lung cancer drug trial fails…

Gilead Sciences: Herber Dämpfer - Aktienanalyse

Kulmbach (www.aktiencheck.de) - Gilead Sciences-Aktienanalyse von "Der Aktionär": Michel Doepke vom Anlegermagazin "Der Aktionär" nimmt in einer aktuellen Aktienanalyse die Aktie…

Gilead Sciences: Studien-Rückschlag – Aktie bricht massiv ein

Zum Start in die neue Handelswoche verliert die Aktie des Biotech-Riesen Gilead Sciences rund zehn Prozent an Wert. Der Grund…

Gilead’s stock tumbles toward biggest selloff in more than 9 years after lung cancer treatment trial disappoints

Shares of Gilead Sciences Inc. tumbled 10.9% beating in premarket trading Monday, to pullback from an 11-month high, after the…

Biotech Market Forecast: Top Trends That Will Affect Biotech in 2024

The biotech sector is a dynamic and constantly evolving industry that is driving scientific advancements and innovation in healthcare. According…

Stocks making the biggest moves midday: Amazon, Lennar, GoodRx, Gilead Sciences and more

These are the stocks posting the largest moves in midday trading.…

Gilead Sciences, Inc. (GILD) J.P. Morgan 42nd Annual Healthcare Conference (Transcript)

…

5 Powerhouse Stocks to Fuel Your 2024 Portfolio

Stocks Analysis by Investing.com (Ismael De La Cruz) covering: Gilead Sciences Inc, Amazon.com Inc, Pfizer Inc, Berkshire Hathaway B. Read…

Gilead Sciences zahlt vierteljährliche Dividende an die Aktionäre

Der Biotechnologiekonzern Gilead Sciences Inc. (ISIN: US3755581036, NASDAQ: GILD) wird an diesem Donnerstag eine Quartalsdividende in Höhe von 0,75 US-Dollar…

Gilead Sciences zahlt vierteljährliche Dividende an die Aktionäre

Der Biotechnologiekonzern Gilead Sciences Inc. (ISIN: US3755581036, NASDAQ: GILD) wird an diesem Donnerstag eine Quartalsdividende in Höhe von 0,75 US-Dollar…

Hookipa Pharma: +100% mit Ansage - wo lauern die nächsten Deals?

Die österreichische Biotech-Hoffnung Hookipa Pharma (WKN: A2PGMT) gab gestern den Erwerb von Unternehmensanteilen durch seinen Entwicklungspartner Gilead Sciences bekannt. Die…

HOOKIPA Pharma Announces $21.25 Million Equity Investment from Gilead Sciences

NEW YORK and VIENNA, Austria, Dec. 21, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a…

Gilead Sciences and Compugen strike commercialization deal for immunotherapy program

Gilead Sciences, Inc. (NASDAQ:GILD) announced that it has entered into an agreement with Compugen Ltd (NASDAQ:CGEN) to exclusively license Compugens...…

Compugen signs cancer drug licensing deal with Gilead Sciences

US biopharmaceutical giant Gilead Sciences Inc. (Nasdaq: GILD) today announced an agreement with Israeli clinical-stage cancer immunotherapy company Compugen…

Global Myasthenia Gravis Treatment Market Forecast and Trends 2023-2028, Featuring Profiles of AbbVie, Bausch Health, Gilead Sciences, Merck, Servier and Teva

Dublin, Dec. 18, 2023 (GLOBE NEWSWIRE) -- The "Global Myasthenia Gravis Treatment Market: Forecast and Trends" report has…

Gilead Sciences: Kursziel reduziert

New York (www.aktiencheck.de) - Rating-Update: Terence Flynn, Analyst von Morgan Stanley, belässt die Aktie von Gilead Sciences Inc. (ISIN: US3755581036, WKN:…

Gilead Sciences Is Building A Diversified Portfolio

…

Gilead Sciences, Inc. (GILD) Presents at Piper Sandler 35th Annual Healthcare Conference (Transcript)

…

Gilead Sciences, Inc. (GILD) Presents at 6th Annual Evercore ISI HealthCONx Conference (Transcript)

…

Oncology Drug Discovery & Development Market Expected to Grow at a CAGR of 18.2% from 2023 to 2031 | Reveals InsightAce Study

Companies covered in this study are Novartis, AstraZeneca, Merck & Co., Inc, Bristol-Myers Squibb, Pfizer, Eli Lilly and Company, Gilead…

dpa-AFX ProFeed